Fig. 1 · Structure

Documents & Downloads

T863

Cat. No. A11386 CAS 701232-20-4

DGAT1 inhibitor

T863 is an orally active, selective and potent DGAT1 (Acyl-CoA:diacylglycerol acyltransferase 1) inhibitor that interacts with the acyl-CoA binding site of DGAT1, and inhibits triacylglycerol synthesis in cells.

In Stock

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Cellular Effect

Cell Line Activity Value Description Reference
CHO-K1 EC50 1.436 μM Inhibition of human DGAT1 expressed in CHO-K1 cells after 1 hr using palmitoyl-1-14C-coenzyme A by phospholipid flashplate assay [PMID: 21413799]
HT-29 IC50 16 nM Inhibition of DGAT1-mediated triglyceride synthesis in human HT-29 cells using [3H]glycerol as substrate after 6 hrs by beta counting [PMID: 24900321]
HT-29 IC50 8 nM Inhibition of human DGAT-1-mediated triglyceride synthesis in the HT-29 cells by whole cell assay [PMID: 21908190]
HuTu80 IC50 0.004 μM Inhibition of triacylglycerol synthesis in human HuTu 80 cells after 30 mins [PMID: 19256504]
Sf9 IC50 0.015 μM Inhibition of human recombinant DGAT1 expressed in Sf9 cells by liquid scintillography [PMID: 19256504]
Sf9 IC50 72 nM Inhibition of full length human microsomal DGAT-1 expressed in baculovirus infected insect Sf9 cells using [14C]decanoylCoA as substrate after 1.5 hrs by scintillation counting [PMID: 24900321]

T863 Research Summary

This section summarizes 2 in vitro studies and 1 in vivo study of T863 from 2 published references. In vitro models include SUM159 breast cancer cells; ACAT1 N487A. In vivo models include C3HeB/FeJ mice.

T863 In Vitro Studies

In SUM159 breast cancer cells incubated in culture medium containing oleic acid, 10 μM T863 reduced lipid droplets by ~50% compared with an equivalent volume of DMSO. In a reaction mixture containing 10 μM T863, the N487A substitution rendered ACAT1 ~40% more sensitive to T863 inhibition compared with wild-type ACAT1. [1]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Lipid droplets in breast cancer cells

Cell-based study · SUM159 breast cancer cells [1]

For LD area experiments, cells were treated with 10 μM T863 (or equivalent volume of DMSO) 30 min prior to the incubation in 0.5 mM oleic acid containing medium. Each inhibitor reduced lipid droplets (LDs) by ~50% in SUM159 cells incubated in a culture medium containing oleic acid.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
LD area (% cytoplasm)LD area (% cytoplasm) ~50%[1]

Literature-Reported Treatment Conditions

Treatment concentration
10 μM
Exposure duration
30 min prior to the incubation; 18 h
Method
cells were treated
Vehicle
DMSO
Co-treatment
Other interventions in this design: oleic acid 0.5 mM. Compound effect isolated by the comparison: equivalent volume of DMSO.
Methods and source locations

Compound reported in the paper: T863

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Results > The DGAT1 inhibitors T863 and DGAT1N1 inhibit recombinant human DGAT1 (S5); Methods > Fluorescence microscopy (S133, S134, S136); Methods > Quantification of fluorescence images (S145); Fig. 1 legend (S177)

LD area (% cytoplasm): LD area (% cytoplasm); comparator: equivalent volume of DMSO — Results > The DGAT1 inhibitors T863 and DGAT1N1 inhibit recombinant human DGAT1 (S5); Methods > Fluorescence microscopy (S134); Methods > Quantification of fluorescence images (S145)

Sensitivity of an ACAT1 substitution to inhibition

Cell-based study · ACAT1 N487A [1]

ACAT1 N487A was evaluated with T863 at 10 μM in a reaction mixture. The substitution rendered ACAT1 ~40% more sensitive to T863 inhibition compared with wild-type ACAT1.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
sensitive to T863 inhibitionsensitivity to T863 inhibition ~40% more sensitive to T863 inhibition[1]

Literature-Reported Treatment Conditions

Treatment concentration
10 μM
Exposure duration
25 °C for 30 min; 37 °C with gentle agitation for 30 min
Method
reaction mixture
Reported limits
Not stated in the sentences used: vehicle.
Methods and source locations

Compound reported in the paper: T863

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Results > Structural basis for selectivity of DGAT1 inhibitors (S59, S72, S73); Methods > DGAT1 and ACAT1 activity assays (S122, S123, S124, S125, S130, S131)

sensitive to T863 inhibition: sensitive to T863 inhibition; comparator: wild-type ACAT1 — Results > Structural basis for selectivity of DGAT1 inhibitors (S72)

T863 In Vivo Studies

In C3HeB/FeJ mice, treatment orally administered at 30mg/kg for 15 consecutive days starting at day-14 post infection resulted in higher oil red O staining in the distal region of the small intestine compared to vehicle treated mice. [2]

Higher Intestinal Oil Red O Staining Following Oral Treatment

Animal study · C3HeB/FeJ mice [2]

In C3HeB/FeJ mice, treatment orally administered at 30mg/kg for 15 consecutive days starting at day-14 post infection resulted in higher oil red O staining in the distal region of the small intestine compared to vehicle treated mice.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
oil red O staining in the distal region of the small intestineReported result higher oil red O staining in the distal region of the small intestine compared to vehicle treated mice[2]

Conditions shared by the study groups

Route
orally administered
Treatment course
for 15 consecutive days starting at day-14 post infection
Vehicle
0.1% carboxymethylcellulose (CMC): 0.1% of Tween-80
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
T863 30mg/kgvehicle treated micehigher oil red O staining in the distal region of the small intestine compared to vehicle treated mice[2]
T863 30mg/kg
Model: C3HeB/FeJ mice
Methods and source locations

Compound reported in the paper: T863

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Results > DGAT1 Regulates Granuloma Triglyceride Levels (S29); Materials and Methods > DGAT1 Inhibitor (T863) Administration (S152, S155); Materials and Methods > Histology for Small Intestine (S162, S165)

oil red O staining in the distal region of the small intestine: oil red O staining in the distal region of the small intestine; comparator: vehicle treated mice — Results > DGAT1 Regulates Granuloma Triglyceride Levels (S29)

T863 30mg/kg · Results > DGAT1 Regulates Granuloma Triglyceride Levels (S29); Materials and Methods > DGAT1 Inhibitor (T863) Administration (S152)

Specifications

Manufacturer Adooq Bioscience
Actions Inhibitor
CAS Number 701232-20-4
Applications DGAT1 inhibitor
Formula C22H26N4O3
Molecular Weight 394.47
SMILES
O=C(O)C[C@H]1CC[C@H](C2=CC=C(C3=NC4=C(N)N=CN=C4OC3(C)C)C=C2)CC1

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 73 mg/mL (185.05 mM)
Water Insoluble
Ethanol 1 mg/mL

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

T863 Research References

  1. [1] Sui X, Wang K, Song K, et al. Mechanism of action for small-molecule inhibitors of triacylglycerol synthesis. Nat Commun (2023). PMID: 37248213 DOI: 10.1038/s41467-023-38934-3 Source material
  2. [2] Dawa S, Menon D, Arumugam P, et al. Inhibition of Granuloma Triglyceride Synthesis Imparts Control of Mycobacterium tuberculosis Through Curtailed Inflammatory Responses. Front Immunol (2021). PMID: 34603294 DOI: 10.3389/fimmu.2021.722735 Source material

Added to your cart

View Cart Checkout
Loading...